Genoa Ventures

ICYMI: Jenny Rooke, Managing Director of Genoa Ventures, shared her insights on Bloomberg Businessweek Live! Dr. Rooke spoke about the future she sees for the biotech space – one that extends beyond drugs and into the fundamental biologies that impact our lives. From new bioplastics to better foods and even dinosaur DNA, she answered the host's and listeners' questions and touched on the potential for innovation. Catch the full 10-minute discussion (starting at 21:56) to hear how #Genoaportcos, including BrightSpec, Inc., Bond Pet Foods, and more, are driving these groundbreaking advancements in the field. https://lnkd.in/dGAXyNP5 #BloombergBusinessweek #GenoaVC #Biotech #EarlyStageInvestments #Investing #PrecisionMedicine

Mercy Medical Center and Hall-Perrine Cancer Center announced a new partnership with SimBioSys, Inc. a #GenoaPortCo, to bring advanced technology to our breast cancer patients. They will implement TumorSight™ Viz, SimBioSys' proprietary technology, which uses AI to determine optimal treatment plans for breast cancer. This AI and 3D imaging technology allows for more precise surgical planning, enabling Mercy Medical Center surgeons to remove the tumor more effectively while also preserving as much healthy tissue as possible. Read more about their collaboration here: https://lnkd.in/eNrV_uDv

#ICYMI: At the Pacific Coast Reproductive Society Annual Meeting, Fellow a #GenoaPortCo, presented findings on how their mail-in semen analysis helps address barriers to test completion related to race, education, and income. Fellow’s Vasectomy Tests and Semen Analysis kits are allowing men to feel comfortable learning about their fertility and other health outcomes in their own homes. The conclusion of the study indicates that the mail-in options are significantly improving patient compliance, with rates rising to 88% compared to the clinical setting where patients traditionally gave sperm samples. Fellows’ semen kit creates awareness and inclusivity around men's health. By producing these patient-empowering analysis kits, men can be educated about their fertility regardless of circumstance. Learn more here: https://lnkd.in/eJUcfQZd

Congratulations to Tropic for securing a spot on the 2024 SVG Ventures | THRIVE Top 50 AgTech & FoodTech Listings. The selected companies represent what is possible in the Agricultural and Food technology landscape, and Tropic’s industry-leading innovations set a new standard for the future of the global agri-food system. Its unique gene editing technology GEiGS®, activates the naturally occurring gene editing and gene silencing mechanisms in tropical crops. Tropic has demonstrated success in programs dedicated to bananas in the Philippines and sugar beets in the UK Food Market. These programs enable disease resistance and improved characteristics, creating solutions for farmers to produce more food and overcome crop diseases. #agtech #sustainability #foodtech #genoaportco

Eager to learn from leaders in biology, technology, engineering, and more? This coming Monday, at the Chan Zuckerberg Biohub Network's "Chicago BioEngineering Conference," Vikram Chaudhery, Partner at #Genoa, will speak on the panel: “Trends in Biomedical Innovation” at 3:45 p.m. CT Don't miss this compelling discussion also featuring: Dan Wattendorf (Bill & Melinda Gates Foundation) Rita Strack (Senior Editor at Nature Magazine) and Milan Mrksich (Henry Wade Rodgers Professor Northwestern University) Grab your tickets from the link below: https://lnkd.in/e5VX_A9G

Welcome water industry veteran Myron Van Ert as the first Chief Commercial Officer at ZwitterCo, a #GenoaPortCo, marking a bold new chapter in global growth! Myron Van Ert joins Zwitterco with nearly 30 years of driving international expansion, including senior leadership roles at Veolia, Myron will be driving the commercial adoption of their revolutionary zwitterionic membrane technology worldwide. “We are thrilled to welcome Myron to the ZwitterCo team as our first Chief Commercial Officer, a pivotal hire that marks a new chapter in our company’s growth,” says CEO Alex Rappaport. https://lnkd.in/ehFMNzBs #Watersustainability #Welcome #CCO

Really good session today on fundraising and term sheets. Genoa Ventures' Vikram Chaudhery: There's now a higher burden on the startup, as investors now looking for more POC points. Diligence is now taking longer, and term sheets are taking an entire quarter to finalize. Also -- realize that you are not necessarily looking for the investor who can give you the highest valuation. A high valuation at an early stage may not be in your long-term interest, because you want to be demonstrating continual growth and increasing value at later stages. BEVC's Widya Mulyasasmita echoed the sentiment, noting "Remember you are probably not fundraising just once. Future-proof so your next round is not down. It is hard for VCs to explain to LPs later on why your investment just had a down round." You don't want to be valued higher than an equivalent public company. Radar Therapeutics' Sophia Lugo had the founder's perspective: It's key to have empathy with the investor, understanding that you have to bring them returns. They have reasons for their valuation and their choices. Understand that you, with your innovative bioscience, are now competing with high-yield bonds for their money (!). You have to be the "best hammer for the nail." Last word from Widya: Reach out to potential investors for advice. "The best time to raise money is when you don't need it." Thanks to Shoaib Ghias from Goodwin for moderating!

In Communications Biology 7, 1086 (2024), Aqtual, Inc. published new research demonstrating the potential of its proprietary platform to evaluate gene regulation, epigenetics, and transcriptomics by analyzing previously unexplored cfDNA fragments found in blood, and opening the door to new clinical applications in almost every major disease area. What is the significance of this research and novel platform? In a recent company press release, Clifford Lowell MD, PhD, Distinguished Professor and Chair at the University of California, San Francisco Dept. of Laboratory Medicine, said, “The simple modification of DNA isolation techniques from plasma samples, allowing for enrichment of longer DNA fragments derived from actively transcribed regions, is a major advancement in the cell-free DNA field. This cell-free DNA sequencing assay can follow the normal circadian rhythm of immune cell gene expression, offering a novel and straightforward method to monitor gene expression profiles in immune and potentially non-immune mediated disease states. It will be exciting to see how this new tool is applied.” Read the full study at the link below Link: https://lnkd.in/e9avCvyT #PrecisionMedicine #cfDNA #RA

Earlier this month, a new FDA rule went into effect requiring women be told about the density of their breasts, and how this might impact their risk of breast cancer. Read the links below for thoughts from SimBioSys, Inc. a #GenoaPortCo, and Vikram Chaudhery, Partner at Genoa Ventures, on how this advancement in helping improve early detection and save lives. At Genoa Ventures, we’re here to support SimBioSys, Inc. as they pioneer innovations like TumorSight™, offering personalized, AI-driven insights to transform breast cancer care. https://lnkd.in/eUMEGtha #BreastCancerAwareness #WomensHealth #SimBioSys #EarlyDetection #PrecisionMedicine #Genoaportco

Don't miss Vikram Chaudhery, Partner at Genoa Ventures, participate in an online discussion on Fundraising Strategies & Negotiating Term Sheets, hosted by QB3 Taking place September 19, 2024, from 2:10 PM to 3:00 PM CT. 📅 Event Link: https://bit.ly/47teWxS Vikram will be offer his expertise, alongside other industry leaders Sophia Lugo CEO and Co-founder of Radar Therapeutics Widya Mulyasasmita Mulyasasmita, General Partner at BEVC Shoaib Ghias Partner at Goodwin (moderator) #Fundraising #TermSheets #VentureCapital #GenoaVentures #StartupTips #QB3Events